Navidea Biopharmaceuticals (NAVB) Initiates Enrollment in Global Phase 3 Trial of NAV4694 PET Imaging Agent
6/27/2013 9:47:24 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the first subject has been enrolled in its NAV4694 global, pivotal Phase 3 clinical trial. The trial will assess the safety and efficacy of NAV4694, an investigational PET imaging agent, in detecting cerebral ß-amyloid in end-of-life subjects with and without the diagnosis of dementia. The study will examine the effectiveness of NAV4694 in detecting the presence or absence of ß-amyloid deposition in the brain by directly correlating the PET image findings during life with those of the brain tissue upon autopsy after death.
Help employers find you! Check out all the jobs and post your resume.
comments powered by